(4-甲基苄基)-肼盐酸盐 | 26177-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-甲基苄基)-肼盐酸盐
• 中文别名: (4-甲基苄基)肼盐酸盐
• 英文名称: p-methylbenzylhydrazine hydrochloride
• 英文别名: (4-methylbenzyl)hydrazine hydrochloride；(4-methyl-benzyl)-hydrazine; monohydrochloride；(4-Methyl-benzyl)-hydrazin; Monohydrochlorid；(4-methylphenyl)methylhydrazine;hydrochloride
• CAS: 26177-51-5
• 化学式: C₈H₁₂N₂*ClH
• 分子量: 172.658
• InChiKey: FZDQALMNASCCIY-UHFFFAOYSA-N

物化性质

• 熔点：
  158-160 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.38
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  D(+)-10-樟脑磺酸 、 (4-甲基苄基)-肼盐酸盐 以 乙醇 为溶剂， 反应 2.0h， 以80%的产率得到((1S,E)-7,7-dimethyl-2-(2-(4-methylbenzyl)hydrazone)bicycle[2.2.1]heptan-1-yl)methanesulfonic acid
  参考文献：
  名称：

  The Role of New Technologies in Defining a Manufacturing Process for PPARα Agonist LY518674

  摘要：

  The impact of several new technologies on the development of a manufacturing process for LV518674 is described. Extensive use of process analytical technology (PAT) throughout development, both at laboratory and pilot-plant scale, enabled data-rich experiments, shortened development cycle times, and obviated the requirement of PAT for process control at larger scale. In situ ReactIR was used to develop a kinetic model for a one-pot preparation of a semicarbazide intermediate. Parallel crystallizers fitted with online focused-beam reflectance measurement (FBRM) and particle vision and measurement (PVM) probes were used in the development of several challenging crystallization processes. Application of the process knowledge afforded by these technologies, combined with the principles of Quality by Design, resulted in excellent purity control throughout the four-step process. A single, 5-min, MS-friendly method capable of separating over 30 components was developed using a combination of chromatography modeling software, sub-2 mu m column technology, and higher-pressure LC equipment. The method was used across all four processing steps, greatly facilitating impurity tracking, and reducing assay time and solvent use by 85% and 93%, respectively.

  DOI：

  10.1021/op8002486
• 作为产物：
  描述：

  2-甲基-2-丙基2-异亚丙基肼羧酸酯 、 4-甲基苄溴 在 sodium hydride 、 盐酸 作用下， 以 乙腈 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 (4-甲基苄基)-肼盐酸盐
  参考文献：
  名称：

  EP1396493

  摘要：

  公开号：

文献信息

• <i>N</i> ‐Amino‐1,8‐Naphthalimide is a Regenerated Protecting Group for Selective Synthesis of Mono‐N‐Substituted Hydrazines and Hydrazides
  作者：Mesram Manoj Kumar、Parikibanda Venkataramana、Parikibanda Yadagiri Swamy、Yadaiah Chityala

  DOI：10.1002/chem.202102593

  日期：2021.12.15

  N-Amino-1,8-naphthalimide was used as a protecting group and a reagent to selective synthesis of various mono-N-substituted hydrazines and hydrazides. In all these reactions, the protecting reagent N-amino-1,8-naphthalimide was easily regenerated in good yields by the hydrazinolysis. All these transformations showed good functional-group tolerance and can be used for large scale C−N cross-coupling

  N-氨基-1,8-萘二甲酰亚胺用作保护基团和试剂，用于选择性合成各种单-N-取代的肼和酰肼。在所有这些反应中，保护试剂N-氨基-1,8-萘二甲酰亚胺很容易通过肼解以良好的产率再生。所有这些转化都显示出良好的官能团耐受性，可用于大规模的 CN 交叉偶联反应。
• PHARMACEUTICAL COMPOSITIONS
  申请人：LAZZARI Paolo

  公开号：US20100216785A1

  公开（公告）日：2010-08-26

  Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, O) from 0.01 to 95% of one or more oils selected from esters of C 4 -C 32 acids or C 4 -C 32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A′: AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.

  药物组成的微乳液包含以下组分（按重量百分比计算），各组分总和为100％：S）从0.01到95％的一种或多种化合物，选自表面活性剂、聚合物，形成有序结构，如：聚集体、胶束、液晶、囊泡，在它们被溶解的液体中，O）从0.01到95％的一种或多种油，选自C4-C32酸酯或C4-C32酸，PA）从0.001到90％的化合物，具有亲和力为公式A'的CB1和/或CB2大麻素受体，AD）从0到60％的一种或多种化合物，按重量计算，选自调节剂，水和/或油极性的调节剂，组分S）的膜曲率调节剂，共表面活性剂，水或盐水溶液之差为100％，其中按重量比S）/PA）低于不含组分O）的微乳液的比例。
• Tricyclic condensed pyrazole derivatives as CB1 inhibitors
  申请人：Neuroscienze Pharmaness S.C. A R.L.

  公开号：EP2223914A1

  公开（公告）日：2010-09-01

  Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I) : wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.

  具有紧凑结构的三环化合物，其中包含一个苯环和一个吡唑环，通过一个含有五至八个原子的中心环相互连接，具有对CB1和/或CB2受体的亲和力，具有中枢神经系统和/或外周活性，化学式为(I)：其中各种取代基如描述中定义。这些化合物显示对CB1和/或CB2大麻素受体的亲和力。
• PHARMACEUTICAL COMPOUNDS
  申请人：LAZZARI Paolo

  公开号：US20100215741A1

  公开（公告）日：2010-08-26

  Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.

  具有紧凑结构的三环化合物，包含一个苯环和一个吡唑环，通过一个由五至八个原子组成的中心环相互连接，在CB1和/或CB2受体上具有亲和力，具有中枢神经系统和/或外周活性，化学式（I）如下：其中各种取代基如描述中所定义。这些化合物对CB1和/或CB2类大麻素受体具有亲和力。
• Pharmaceutical compounds
  申请人：Neuroscienze Pharmaness S.C. A R.L.

  公开号：EP2230243A1

  公开（公告）日：2010-09-22

  Condensed tricyclic pyrazole compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors, with activity both on the peripheral and central nervous system, of formula (I) : wherein: A represents a group selected from -(CH2)t-, -(CH2)r-O-(CH2)s- and -(CH2)r-S(O)p-(CH2)s- B is an heteroaryl, R is a group selected from heteroaryl, heteroarylalkyl, aryl, arylalkyl, arylalkenyl or bivalent aliphatic chain, R' is a group selected from the following: R'1: a substituent bearing a keto group of formula -C(O)-(Z')v-Z" R'2: a substituent having an hydroxylic function of formula -CH(OH)-(Z')v-Z", R'3: an amide substituent of formula -C(O)-NH-(Z')v-T'.

  具有对CB1和/或CB2大麻素受体亲和力的紧凑三环吡唑化合物，对外周和中枢神经系统均具有活性，其化学式为(I)：其中：A代表从-(CH2)t-, -(CH2)r-O-(CH2)s-和-(CH2)r-S(O)p-(CH2)s-B中选择的基团，B是杂芳基，R是从杂芳基、杂芳烷基、芳基、芳基烷基、芳基烯基或二价脂肪链中选择的基团，R'是从以下选择的基团：R'1：具有化学式-C(O)-(Z')v-Z"的酮基团的取代基，R'2：具有化学式-CH(OH)-(Z')v-Z"的羟基功能的取代基，R'3：具有化学式-C(O)-NH-(Z')v-T'的酰胺取代基。